prikaz prve stranice dokumenta Safety and efficacy of fluvoxamine in COVID‐19 ICU patients: An open label, prospective cohort trial with matched controls
  Download
PDF 1.81 MB
Scientific paper - Original scientific paper
Safety and efficacy of fluvoxamine in COVID‐19 ICU patients: An open label, prospective cohort trial with matched controls
British Journal of Clinical Pharmacology, 88 (2022), 5; 2065-2073. https://doi.org/10.1111/bcp.15126
Čalušić, Martina; Marčec, Robert; Lukša, Lea; Jurković, Ivan; Kovač, Nataša; Mihaljević, Slobodan; Likić, Robert

Institutional repository: Dr Med - University of Zagreb School of Medicine Digital Repository

Cite this document

Čalušić, M., Marčec, R., Lukša, L., Jurković, I., Kovač, N., Mihaljević, S. & Likić, R. (2022). Safety and efficacy of fluvoxamine in COVID‐19 ICU patients: An open label, prospective cohort trial with matched controls. British Journal of Clinical Pharmacology, 88. (5), 2065-2073. doi: 10.1111/bcp.15126

Čalušić, Martina, et al. "Safety and efficacy of fluvoxamine in COVID‐19 ICU patients: An open label, prospective cohort trial with matched controls." British Journal of Clinical Pharmacology, vol. 88, no. 5, 2022, pp. 2065-2073. https://doi.org/10.1111/bcp.15126

Čalušić, Martina, Robert Marčec, Lea Lukša, Ivan Jurković, Nataša Kovač, Slobodan Mihaljević and Robert Likić. "Safety and efficacy of fluvoxamine in COVID‐19 ICU patients: An open label, prospective cohort trial with matched controls." British Journal of Clinical Pharmacology 88, no. 5 (2022): 2065-2073. https://doi.org/10.1111/bcp.15126

Čalušić, M., et al. (2022) 'Safety and efficacy of fluvoxamine in COVID‐19 ICU patients: An open label, prospective cohort trial with matched controls', British Journal of Clinical Pharmacology, 88(5), pp. 2065-2073. doi: 10.1111/bcp.15126

Čalušić M, Marčec R, Lukša L, Jurković I, Kovač N, Mihaljević S, and sur.. Safety and efficacy of fluvoxamine in COVID‐19 ICU patients: An open label, prospective cohort trial with matched controls. British Journal of Clinical Pharmacology [Internet]. 2022 May [cited 2024 November 22];88(5):2065-2073. doi: 10.1111/bcp.15126

M. Čalušić, et al., "Safety and efficacy of fluvoxamine in COVID‐19 ICU patients: An open label, prospective cohort trial with matched controls", British Journal of Clinical Pharmacology, vol. 88, no. 5, pp. 2065-2073, May 2022. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:224631. [Accessed: 22 November 2024]

Metadata
Title (english)Safety and efficacy of fluvoxamine in COVID‐19 ICU patients: An open label, prospective cohort trial with matched controls
AuthorMartina Čalušić
AuthorRobert Marčec
AuthorLea Lukša
AuthorIvan Jurković
AuthorNataša Kovač
AuthorSlobodan Mihaljević
AuthorRobert Likić
Author's institutionUniversity of Zagreb
School of Medicine
(Department of Anaesthesiology, Resuscitation and Intensive Care in Surgical Specialities)
Author's institutionUniversity of Zagreb
School of Medicine
(Department of Internal Medicine)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Anesthesiology and Reanimatology
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Internal Medicine
Abstract (english)
Aims: Fluvoxamine, a selective serotonin reuptake inhibitor (SSRI) and sigma-1 receptor agonist, has so far shown promise in the prevention of COVID-19 progression as an early treatment option in three trials. The aim of this study was to evaluate the safety and efficacy of fluvoxamine in COVID-19 patients if administered later in the course of the disease. ----- Methods: The study was designed as an open-label, prospective cohort trial with matched controls. In April and May 2021, 51 ICU COVID-19 patients hospitalised in the University Hospital Dubrava and University Hospital Centre Zagreb, Croatia, were treated with fluvoxamine 100 mg three times daily for 15 days in addition to standard therapy and they were prospectively matched for age, gender, vaccination against COVID-19, disease severity and comorbidities with 51 ICU controls. ----- Results: No statistically significant differences between groups were observed regarding the number of days on ventilator support, duration of ICU or total hospital stay. However, overall mortality was lower in the fluvoxamine group, 58.8% (n = 30/51), than in the control group, 76.5% (n = 39/51), HR 0.58, 95% CI (0.36-0.94, P = .027). ----- Conclusion: Fluvoxamine treatment in addition to the standard therapy in hospitalised ICU COVID-19 patients could have a positive impact on patient survival. Further studies on the effects of fluvoxamine in COVID-19 patients are urgently required.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleBritish Journal of Clinical Pharmacology
Numberingvol. 88, no. 5, pp. 2065-2073
p-ISSN0306-5251
e-ISSN1365-2125
DOIhttps://doi.org/10.1111/bcp.15126
URN:NBNurn:nbn:hr:105:224631
Publication2022-05
Document URLhttps://onlinelibrary.wiley.com/doi/10.1111/bcp.15126
Type of resourceText
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2022-06-28 07:27:42